GE Healthcare’s gas-based MRI imaging strategy may find a home, if tests of the technology by Merck pan out. The pharmaceutical company plans to audition GE’s Spin Signal Technology (SST) utilizing hyperpolarized xenon 129 gas for use in assessing its experimental respiratory treatments.
GE Healthcare's gas-based MRI imaging strategy may find a home, if tests of the technology by Merck pan out. The pharmaceutical company plans to audition GE's Spin Signal Technology (SST) utilizing hyperpolarized xenon 129 gas for use in assessing its experimental respiratory treatments.
GE Healthcare has granted Merck access to the technology and its novel molecular imaging agent, which allows quantitative MR imaging of the lungs. Merck will assess whether SST is more sensitive than currently available tests used to gauge the function of diseased lungs.GE Healthcare has been looking for viable commercial applications for the technology since acquiring the rights following its merger with Amersham in 2004.
Could Ultrafast MRI Enhance Detection of Malignant Foci for Breast Cancer?
April 10th 2025In a new study involving over 120 women, nearly two-thirds of whom had a family history of breast cancer, ultrafast MRI findings revealed a 5 percent increase in malignancy risk for each second increase in the difference between lesion and background parenchymal enhancement (BPE) time to enhancement (TTE).
MRI Study Suggests Shape of White Matter Hyperintensities May Be Predictive of Cognitive Decline
April 7th 2025Emerging research demonstrated that cognitive declines in memory, executive function and processing speed domains were associated with irregular shape of periventricular/confluent white matter hyperintensities.
Can Abbreviated MRI Have an Impact in Rectal Cancer Staging?
April 4th 2025Abbreviated MRI demonstrated a 95.3 percent specificity for rectal cancer and provided strong agreement with the full MRI protocol for T staging and detection of extramural venous invasion, according to newly published research.